Description
Cell-permeable. An ethyl ester derivative of the JMJD3 selective histone demethylase inhibitor GSK-J1 (IC50> 50 µM in vitro. When administered to human primary macrophages, GSK-J4 can reduce lipopolysaccharide (LPS)-induced proinflammatory cytokine production, most notably including that of TNFα (IC50 = 9 µM)